title: Company reply to "Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin".
authors.affiliation: Medical Affairs, Hematology and Transplantation Europe, Sanofi, Paris, France. Electronic address: suzanne.janssen@sanofi.com.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Janssen
authors.affiliation: Medical Affairs, Oncology, Hematology and Transplantation Europe, Sanofi, Paris, France.
authors.forename: Karin
authors.initials: K
authors.lastname: Blakolmer
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D000961:Antilymphocyte Serum